2001 Cannabinoids Clinical Trials Consumption 
The Cannigma
MAY 19, 2021
In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. In 2018, Epidolex became the first plant-derived cannabinoid prescription medicine to receive FDA approval. Shutterstock).
CannaTech
SEPTEMBER 16, 2018
Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. Over time extended clinical trials will continue to map out the plant’s therapeutic effects, supporting it as an alternative medicine offering relief for a long list of conditions. Changing Cannabis Conversations Worldwide.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CannaMD
AUGUST 26, 2020
A new review published by scientific journal, Pharmacology Biochemistry and Behavior , has found that marijuana cannabinoid, CBD, is a “promising” therapy for treating cocaine dependence. Exploring alternative therapies, researchers turned their attention to marijuana cannabinoid, cannabidiol – more commonly referred to as CBD.
The Cannigma
JANUARY 13, 2023
Treating migraine pain is one of the instances where inhaled cannabis consumption, such as smoking or vaping , is important for the right effects and speed of delivery. Since pain and nausea are two of the most common symptoms of migraines, this cannabinoid is of great scientific interest in helping people who suffer from migraines.
Cannabis Law Report
JUNE 10, 2021
The authors share this view, assessing that the current evidence shows that marijuana can impair driving ability and increase crash risk, especially shortly after consumption. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. Cannabis Cannabinoid Res. A meta-analysis by Asbridge et al.
Cannabis Law Report
NOVEMBER 24, 2021
The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). Only one article appeared in the MJA in 2000 and again in 2001. 2016 ; Sznitman et al. years (Atakan 2012 ). Discussion.
Cannabis Law Report
JULY 12, 2019
International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.
Expert insights. Personalized for you.
137 
Let's personalize your content